EUCTR2009-014940-12-HU进行中（未招募）1 期
Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female patients.
- •- Aged between 18 and 75 years (inclusive).
- •- ICD for primary or secondary prevention of ventricular arrhythmia for at least 3 months before selection.
- •- Symptomatic CHF for at least 6 months before selection.
- •- NYHA functional class II or III.
- •- Ischemic disease or idiopathic dilated cardiomyopathy as main cause for CHF.
- •- Treatment with a beta-blocker for at least 3 months before selection.
- •- An average number of at least 100 premature ventricular complexes (PVCs) per hour on a 48-hour Holter ECG recording.
- •- LVEF = 40% at echocardiographic examination.
- •- Sinus rhythm.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Unstable condition within 4 weeks before selection.
- •- Recent (less than 3 months before selection) myocardial infarction, unstable angina or coronary revascularisation.
- •- History of stroke or cerebral transient ischemic attack within 3 months before selection.
- •- Severe primary aortic or mitral stenosis or regurgitation.
- •- Congenital heart disease.
- •- Hypertrophic obstructive cardiomyopathy.
- •- Cardiac resynchronisation therapy (CRT) started within 6 months before selection.
- •- Episode of reverted ventricular fibrillation or Torsade de Pointes within 4 weeks before selection.
- •- Atrio-ventricular block of second or third degree.
- •- Corrected QT interval duration (Bazett’s formula) > 480 ms.
研究者
相似试验
已完成
2 期
Evaluation of the anti-arrhythmic effects of 3 oral dosages of S44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.failure of the heart pump function10019280NL-OMON35783Servier R&D Benelux5
进行中（未招募）
1 期
Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction at risk for ventricular arrhythmia. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study.EUCTR2009-014940-12-FRInstitut de Recherches Internationales Servier160
进行中（未招募）
1 期
Evaluation of the antiarrhythmic effects of 3 dosages of S 44121 versus placebo in patients with chronic heart failure at risk for ventricular arrhythmia.Chronic Heart Failure and left ventricular systolic dysfunction at risk for ventricular arrhythmiaMedDRA version: 14.1Level: PTClassification code 10049694Term: Left ventricular dysfunctionSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: PTClassification code 10007558Term: Cardiac failure chronicSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: PTClassification code 10047281Term: Ventricular arrhythmiaSystem Organ Class: 10007541 - Cardiac disordersEUCTR2009-014940-12-BEInstitut de Recherches Internationales Servier160
已完成
2 期
Evaluation of the anti-arrhythmic effects of 3 dosages of S 44121 versus placebo in patients with chronic heart failure at risk for ventricular arrhythmiaCardiac arrhythmia in chronic heart failureCirculatory SystemOther cardiac arrhythmiasISRCTN14227980Institut de Recherches Internationales Servier (France)149
进行中（未招募）
不适用
Evaluation of the antiarrhythmic effects of 3 dosages of S 44121 versus placebo in patients with chronic heart failure at risk for ventricular arrhythmia.Chronic Heart Failure and left ventricular systolic dysfunction at risk for ventricular arrhythmiaMedDRA version: 14.1Level: PTClassification code 10049694Term: Left ventricular dysfunctionSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: PTClassification code 10007558Term: Cardiac failure chronicSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: PTClassification code 10047281Term: Ventricular arrhythmiaSystem Organ Class: 10007541 - Cardiac disordersEUCTR2009-014940-12-DEInstitut de Recherches Internationales Servier160